Loading
The next-generation ROS1 and TRK inhibitor repotrectinib shrank tumours in almost four in five untreated patients with ROS1-positive lung cancer, kept the disease under control for nearly three years, and worked in about four in ten patients after crizotinib including those with the resistant G2032R mutation.
Phase 1/2 study of 171 patients with ROS1 fusion-positive non-small-cell lung cancer treated with repotrectinib, including 71 who had not received a ROS1 inhibitor and 56 previously treated with one.
In ROS1 inhibitor-naive patients, objective response was 79 percent with median progression-free survival 35.7 months; in patients after one prior ROS1 inhibitor without chemotherapy, response was 38 percent with median progression-free survival 9.0 months, and 59 percent of G2032R-mutant tumours responded. Dizziness was the most frequent side effect.
Repotrectinib is a preferred first-line ROS1 inhibitor because of its durability and coverage of resistance mutations, and it is also approved for NTRK fusion-positive tumours after prior TRK inhibitors.
Shares Repotrectinib, ROS1-positive non-small-cell lung cancer.
Shares NTRK fusion-positive non-small-cell lung cancer, New England Journal of Medicine.
Shares Repotrectinib, ROS1-positive non-small-cell lung cancer.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer.
Shares A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements, Repotrectinib, ROS1-positive non-small-cell lung cancer.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer.
Shares A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements, NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer.